Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK4 | O96013 | 1/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 11/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18325952 | 0.91 | GABRA5 (0.42) | PAK4GABRA5HTR1ALRRK2 | |
| SCHEMBL29999947 | 0.90 | PAK4 (0.42) | PAK4GABRA5HTR1ADRD2DRD4 | |
| SCHEMBL18329053 | 0.90 | PAK4 (0.42) | PAK4GABRA5HTR1ADRD2DRD4 | |
| SCHEMBL16345086 | 0.88 | PAK4 (0.41) | PAK4GABRA5HTR1ALRRK2 | |
| SCHEMBL29611543 | 0.88 | PAK4 (0.41) | PAK4GABRA5HTR1ALRRK2 | |
| SCHEMBL18317259 | 0.85 | PAK4 (0.64) | PAK4GABRA5HTR1ALRRK2 | |
| SCHEMBL31622687 | 0.85 | PAK4 (0.64) | PAK4GABRA5HTR1ALRRK2 | |
| SCHEMBL16345871 | 0.85 | PAK4 (0.64) | PAK4GABRA5HTR1ALRRK2 | |
| SCHEMBL16345167 | 0.84 | PAK4 (0.57) | PAK4GABRA5HTR1ALRRK2 | |
| SCHEMBL18317602 | 0.83 | GABRA5 (0.40) | PAK4GABRA5HTR1ALRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210403459-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2021-12-30 | — | — | US | disclosed |
| US-11008309-B2 | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof | Karyopharm Therapeutics Inc. (US) | 2021-05-18 | — | — | US | disclosed |
| US-20200102292-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2020-04-02 | — | — | US | disclosed |
| US-10399963-B2 | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof | Karyopharm Therapeutics Inc. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180319779-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2018-11-08 | — | — | US | disclosed |
| US-9856241-B2 | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof | Karyopharm Therapeutics Inc. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160368904-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2016-12-22 | — | — | US | disclosed |
| EP-3016946-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics, Inc. (US) | 2016-05-11 | — | — | EP | disclosed |
| WO-2015003166-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. (US) | 2015-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368904-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | BCL6, MALT1, BTK | PAK4 2007/4885GABRA5 55/4885HTR1A 2884/4885 |
| US-20180319779-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | BCL6, MALT1, BTK | PAK4 2260/4885GABRA5 48/4885HTR1A 3231/4885 |
| US-11008309-B2 | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof | BCL6, MALT1, BTK | PAK4 2260/4885GABRA5 48/4885HTR1A 3231/4885 |
| US-10399963-B2 | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof | BCL6, MALT1, BTK | PAK4 2260/4885GABRA5 48/4885HTR1A 3231/4885 |
| US-20210403459-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | BCL6, MALT1, BTK | PAK4 2260/4885GABRA5 48/4885HTR1A 3231/4885 |
| US-20200102292-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | BCL6, MALT1, BTK | PAK4 2260/4885GABRA5 48/4885HTR1A 3231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.